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Abstract: Mitochondrial toxicity can be one of the most dreadful consequences of exposure 
to a wide range of external agents including pathogens, therapeutic agents, abuse drugs, toxic 
gases and other harmful chemical substances. However, little is known about the effects of 
mitochondrial toxicity on pregnant women exposed to these agents that may exert 
transplacental activity and condition fetal remodeling. It has been hypothesized that 
mitochondrial toxicity may be involved in some adverse obstetric outcomes. In the present 
study, we investigated the association between exposure to mitochondrial toxic agents and 
pathologic conditions ranging from fertility defects, detrimental fetal development and 
impaired newborn health due to intra-uterine exposure. We have reviewed data from studies 
in human subjects to propose mechanisms of mitochondrial toxicity that could be associated 
with the symptoms present in both exposed pregnant and fetal patients. Since some 
therapeutic interventions or accidental exposure cannot be avoided, further research is 
needed to gain insight into the molecular pathways leading to mitochondrial toxicity  
during pregnancy. The ultimate objective of these studies should be to reduce the 
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mitochondrial toxicity of these agents and establish biomarkers for gestational monitoring 
of harmful effects. 
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1. Introduction 
1.1. Mitochondrial Physiology 
Mitochondria are cell organelles located in the cytoplasm of most of the eukaryotic cells [1]. 
Mitochondria are essential for cell viability because of their involvement in many important processes, 
such as heat production, energy supply, cell respiration, calcium homeostasis and the anabolism and 
catabolism of numerous metabolites [2], among others. However, in pathological conditions, 
mitochondria are also the main source of reactive oxygen species (ROS) production and apoptosis.  
These organelles are the energy powerhouse of cells as they provide energy through the formation of 
molecules of adenosine triphosphate (ATP), the major energy source of the cells. The synthesis of ATP is 
coupled to cell respiration and oxygen consumption in the mitochondrial respiratory chain (MRC).  
Mitochondria are constituted by a double membrane; the external membrane, which is permeable to 
many solutes and makes the interchange of molecules with the cytosol possible, and the internal 
membrane, which is highly impermeable and is a folded structure constituting the mitochondrial cristae, 
where the enzymatic complexes of the MRC are located. Together with chloroplasts, mitochondria are 
the only organelles containing their own genetic material, the mitochondrial DNA (mtDNA) encoding 
for some proteins of the MRC and autonomous transcriptional and translational machinery. Human 
mtDNA is a 16.6 kb double-stranded circular and covalently closed molecule encoding for 13 MRC 
proteins, two mitochondrial ribosomal RNA and 22 mitochondrial transfer RNA essential for the 
translation of mitochondrial-encoded proteins [3]. The remaining proteins located in the mitochondria 
(approximately 1500 in mammals) are encoded in the nucleus. Consequently, intergenomic 
communication between these two entities is essential for adequate mitochondrial function. In this 
context, a decrease of mtDNA levels (mtDNA depletion) can ultimately lead to severe mitochondrial 
dysfunction and energetic cell impairment. Additionally, mitochondrial disarrangements can arise 
during many other steps of mitochondrial function (biogenesis, bioenergetics, dynamics or turnover), 
independently of mtDNA depletion. 
Mitochondrial DNA is exclusively transmitted by the maternal lineage, contrarily to nuclear DNA that 
is transmitted by both parents, and the variation in number of both mitochondria and mtDNA content varies 
widely depending on the cell type and stage of development. Somatic cells contain from hundreds to 
thousands of mitochondria, each carrying from 2 to 10 genomes per organelle [3], and postmitotic tissues, 
which are highly-energetic and dependent on oxidative metabolism, present higher loads of mitochondria 
and mtDNA content. Accordingly, a physiologic state associated with a high energy demand, such as 
fertilization and pregnancy, may require greater mitochondrial activity. 
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The oocyte is the only reproductive cell that provides mitochondrial load to the future embryo and 
posterior newborn. Thus, mitochondria are maternally inherited and a sufficient energy supply from 
oocyte mitochondria is critical to trigger oocyte viability and future embryo development. The oocyte is 
the largest human cell (on average 300 times bigger than other somatic cells) and contains a large amount 
of mitochondria that represent at least 23% of the ooplasm [4]. Depending on the stage of development 
of the germinal cells, the number of mitochondria present ranges widely from 10 in germinal cells, 1000 
in blastocytes to 100,000 in mature oocytes. Oocytes are packed with mitochondria, each of which has 
its own genome. The mtDNA copy number per mature human oocyte is about 100,000–600,000 
molecules, compared with the 500–10,000 molecules for the remaining somatic cells [5,6]. However, 
this very large number of mtDNA per oocyte is not due to increased mtDNA content per mitochondria 
but rather to an increased number of mitochondria per oocyte. In fact, along oogenesis, the number of 
copies of mtDNA is thought to be reduced per organelle in a process known as the mitochondrial 
bottleneck. The aim of this evolutionary strategy is to finally contain one mtDNA molecule per 
mitochondrion to avoid heteroplasmic segregation through the maternal lineage [7], thereby avoiding 
the coexistence of wild type and mutated molecules of mtDNA within the same entity (mitochondria, 
oocyte and future embryo). However, this makes oocyte mitochondria especially vulnerable to mtDNA 
depletion and also makes oocytes especially sensitive to factors causing mtDNA depletion or 
mutagenesis, such as infections, drugs and toxic substances, among others.  
The involvement of mitochondria in fertility outcome can be easily estimated in vitro. It has been 
reported that 50% of human in vitro fertilization (IVF) attempts fail during the first week of  
development [8]. The main causes of this developmental failure, apart from chromosomic alterations [9] 
(deficiency in oocyte maturation [10], lack of activation of embryonic genome [11] or sub-optimal 
culture conditions of both gametes and embryos [12,13]) have been directly or indirectly related to 
mitochondrial function and ROS production. Cohen et al. reported that ooplasm transfer from a young 
donor oocyte into a non-fertile oocyte partially restores the reproductive capacity in the oopausic oocyte, 
and they suggested that “fertility” restoration may be due to mitochondrial transference [14].  
Other studies have shown that both mitochondrial and mtDNA content reflect oocyte variability and 
fertilization outcome [4]. Thus, in vitro studies have suggested that mitochondria in the oocyte contribute 
to successful fertilization and embryonic development. 
Although spermatozoa do not provide mitochondria to the future embryo, mitochondrial function is 
essential for flagellum motility and male fertility in the spermatozoa. 
Once fertilization and implantation have been achieved, mitochondrial activity is essential along 
pregnancy to provide energy and metabolites for the development of the embryo. Blastocytes and future 
embryo cells need an enormous supply of energy to feed constant cell division, migration and 
differentiation. Additionally, mitochondria regulate apoptosis development in this crucial stage of life 
to decide which cells or tissues need to be eliminated for further embryo development. Consequently, 
exposure of mitochondria to toxic agents during pregnancy can alter the development of the embryo and 
may have important consequences in the perinatal outcome and health of the newborn. 
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1.2. Mitochondrial Pathology 
Mitochondria are essential for life and the presence of mitochondrial alterations in a given organism 
may lead to the development of mitochondriopathies [15]. Mitochondrial diseases are classified as 
inherited or acquired (derived from toxic substances), with both sharing similar clinical consequences.  
Mitochondria are present in almost all the tissues of the organism, and therefore mitochondrial 
diseases can be translated into a wide spectrum of clinical manifestations [16]. Mitochondrial diseases 
lack therapeutic treatments and are characterized by the degeneration of tissues, especially those which 
are highly energetic such as muscle and nervous tissue. The symptoms range from myopathy, 
neuropathy, encephalopathy, lactic acidosis, to lipodystrophy or deafness [15]. In the context of 
pregnancy, mitochondrial dysfunction has been associated with increased rates of preterm delivery, 
stillbirth, intrauterine growth restriction (IUGR), and sudden infant death [17]. 
The mutations responsible for genetic mitochondrial diseases can be present in both the nuclear or 
mitochondrial genome. Genetic mitochondrial diseases are present in 1 in 5000 newborns and 1 in  
200 women may carry one of these deleterious mutations. Nuclear mutations are paternal and maternally 
inherited due to Mendelian heritance and can be prevented through genetic counseling and  
pre-implantational diagnosis. However, inherited or acquired mutations in mtDNA present a  
random maternal inheritance pattern due to heteroplasmy that hampers both the diagnosis and prevention 
of mitochondrial diseases.  
Genetically inherited mitochondrial diseases affect the offspring of carriers of nuclear or mtDNA 
mutations. However, acquired mitochondrial diseases are potentially caused by exposure to multiple 
exogenous factors such as: biologic agents, therapeutic drugs, abuse drugs, toxic gases and chemical 
substances, regardless of the genetic environment. 
These toxic compounds usually exert their damaging effects by impairing a specific genetic, 
biochemical or molecular mitochondrial pathway [18]. Nonetheless, in cases of chronic abuse, most of 
these toxic agents finally lead to general mitochondrial dysfunction which can compromise cellular and 
tissue viability and, in some cases, be life threatening [17]. Mitochondrial recovery may occur once the 
exogenous toxicant is withdrawn [19], and the clinical effects caused by these agents normally disappear 
with discontinuation of exposure. However, when this is not possible, clinicians must manage the 
secondary effects caused by mitochondrial toxicity. Mitochondrial therapies designed to revert 
mitochondrial-induced damage (such as antioxidants or vitamins, among others) are currently being 
developed but, are not yet available in routine clinical practice, especially for the management of 
pregnancy or newborns. These treatments involve symptomatic and supportive therapies. Thus, to date, 
the prevention of mitochondrial acquired diseases and mitochondrial toxicity is the prophylactic 
therapeutic option of choice [20]. 
Although mitochondrial toxicity has been widely studied in adults, there is relatively little information 
on these toxicities within the context of human pregnancy, particularly intra utero exposure and the 
potential impact on fetal development and the future of the newborn. The objective of this work was, 
therefore, to review mitochondrial toxicity in fertility and human pregnancies.  
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2. Methods 
We reviewed all the literature concerning fertilization, obstetric and perinatal outcomes due to 
exposure to any mitochondrial toxic agent in humans as an update on the studies performed in these 
areas in the last 10 years. 
We performed a systematic review through PubMed/MEDLINE using keyword search terms related 
to mitochondrial toxic agents, in the English language, and involving human participants.  
The literature review included all the articles published in peer-review journals related to data on 
mitochondrial toxicity in pregnancies exposed to toxic compounds, following the same model of 
mitochondrial studies of toxicities derived from exposure to determined toxic agents described in  
non-pregnant adults. The literature review was conducted with searches in PubMed using combinations 
of the fixed medical subject headings (MeSH): pregnancy and mitochondria, together with the variable 
headings, related to poisonous exposure agents. A significant amount of literature was found with the 
association of mitochondria and pregnancies. However, in most cases, the number of documents 
available considerably decreased when a third factor, related to the toxic agent, was added to the search.  
Except for some punctual cases, we restricted our review to material published in the last 10 years 
(2004–2014) to obtain the most recent information in this field. 
All English language articles with a full-text version reporting data about mitochondrial toxicity in 
human pregnancies exposed to toxic agents with potential capability of causing mitochondrial alterations 
were included in the review. Articles lacking an English abstract were excluded.  
The references of these articles were also scanned for potential additional material, but this did not yield 
many studies fulfilling the study criteria. Studies including animal models or information of highly 
specific basic sciences were excluded from the present review, except for those describing the 
mechanism of toxicity of a studied agent or those needed to reinforce the strong need for further research 
in human pregnancies due to extensive evidence of toxicity in experimental models.  
We found very few studies describing an association between mitochondrial toxicity and human 
pregnancy or reproductive outcome with respect to fertilization or fetal development. Nonetheless, we have 
summarized the information available regarding exposure to: biologic agents (human immunodeficiency 
virus, HIV and hepatitis C virus, HCV), drugs (antivirals, antipsychotics, antibiotics, hypolipemia drugs, 
antidiabetics, non-steroidal anti-inflammatory drugs (NSAIDs), anaesthetics, chemotherapy drugs, 
antiarrhythmics, antimalarials and fungicides), abuse drugs (such as tobacco and alcohol), toxic gases 
(as carbon monoxide) and chemical substances (including pesticides).  
3. Results 
3.1. Mitochondrial Toxicity of Biologic Agents during Pregnancy; The Effect of HCV or HIV 
Both HCV and/or HIV-pregnancies have been associated with an increased frequency of adverse 
obstetric and perinatal outcomes both of which result in maternal or neonatal complications [21,22]. 
The HCV has recently been related to an increase of oxidative stress and mtDNA alterations in  
non-pregnant infected patients. However, to our knowledge, scarce information is available on  
HCV-infected pregnant women to assess viral-mediated mitochondrial damage and its association with 
adverse perinatal outcomes [23].  
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The mechanisms underlying vertical transmission of HCV are poorly understood. Intrauterine 
transmission during pregnancy and infection at the time of delivery are both possible. To date, no special 
measures are taken for HCV-pregnancies to avoid mother-to-child transmission (MTCT).  
On the other hand, in non-pregnant patients, HIV is known to cause diffuse mitochondrial impairment 
by promoting cell death through apoptosis triggered by certain viral proteins [24]. Mitochondrial 
alterations associated with HIV itself were first described in 2002 [25] in a study in which mtDNA 
depletion was reported in peripheral blood mononuclear cells (PBMC) of HIV-patients who had never 
received antiretroviral (ARV) therapy [25]. Thereafter, mitochondrial dysfunction was also 
demonstrated in naïve patients [26]. However, only a few studies have analyzed the toxic mitochondrial 
effects of HIV-infection in human pregnancies.  
The exact mechanism of MTCT of HIV remains unknown. Transmission may occur during 
intrauterine life, delivery, or breastfeeding. Advanced maternal disease, probably due to high viral load, 
is the greatest risk factor for vertical transmission. Untreated HIV-pregnancies are associated with high 
transmission rates of up to 25–30%. With the implementation of universal prenatal HIV-testing, 
counseling, ARV medication, delivery by cesarean section prior to the onset of labor, and avoidance of 
breastfeeding, MTCT has decreased to less than 1–2% in developed countries [27,28]. 
The administration of ARV to avoid HIV-MTCT has reduced viral burdens at delivery and, 
consequently, viral-mediated mitochondrial damage should be minimal [29]. However, some antiviral 
drugs have been shown to cause secondary mitochondrial toxicity. These adverse effects during 
pregnancy are reviewed below in the section on “Drugs”. Most of the studies reporting mitochondrial 
damage in perinatal HIV-exposed newborns include information about transplacentally ARV-derived 
adverse effects, rather than describe the effects of the virus itself, regardless of the therapy used. 
However, the inflammatory environment created by both the HCV and HIV (pro-inflammatory cytokine 
expression or humoral and cellular immune activation, among others) [30] may also reduce the fertility 
and pregnancy outcome of infected women independently of ARV. Thus, further research on 
mitochondrial toxicity due to viral infection during pregnancy is required for better understanding of 
mitochondrial implications in obstetric outcomes in these pregnancies.  
3.2. Drugs 
3.2.1. Antivirals 
Concerning antivirals against HIV, international guidelines recommend the administration of ARV, 
at least during the last trimester of gestation, to decrease the viral load at delivery and the risk  
of MTCT. 
The potential clinical risks associated with ARV exposure in HIV-pregnant women, fetuses and 
infants have been described in observational studies with varying degrees of evidence and conflicting 
results [31–35]. Antiretroviral drugs are essential in the treatment and prevention of HIV-infection and 
transmission. Although their use before, during and after pregnancy is considered safe for both the 
mother and child, there are still lingering concerns about their long-term health consequences and the 
ramifications of their effects on lipid, glucose, intermediary and mitochondrial metabolism [36]. 
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Additionally, ARV have been associated with adverse pregnancy outcomes such as preeclampsia, stillbirth, 
preterm birth and low birth weight, although controversial results have been published [37–41].  
Antiretroviral-driven mitochondrial toxicity has been especially associated with the administration of 
nucleoside analogs which are known to inhibit the mitochondrial enzyme responsible for mtDNA 
replication and repair (DNA polymerase gamma), reviewed in [42]. Nucleoside analog treatment has 
been widely associated with mtDNA point mutations, deletions and depletion responsible for adverse 
manifestations in treated patients including lactic acidosis, lipodystrophy as well as infertility [43]. 
Infertile HIV-infected women on highly active ARV therapy showed oocyte mtDNA depletion of 32%, 
which was even greater in HIV-infected women who failed to become pregnant after IVF [44].  
The authors of this study did not find any correlation between mtDNA oocyte content and the 
immunovirological status of pregnant women. Additionally, oocytes have no HIV-receptors for viral 
entrance, suggesting that the alterations detected may be due to drug toxicity rather than viral infection. 
The mitochondrial toxicity of ARV may trigger the impairment of female fertility but, additionally, when 
pregnancy is achieved, mitochondrial toxicity may increase adverse human pregnancy outcomes. Negative 
mitochondrial and clinical effects of ARV therapy have been reported in HIV-pregnancies [45].  
Most of the mitochondrial studies performed in HIV-pregnancies have described an increased 
frequency of adverse obstetric events in the HIV-cohort [45–49]. Some controversial results in  
HIV-exposed infants reported increased levels of fetal leukocyte mtDNA content [50] accompanied by 
reduced umbilical cord blood mitochondrial enzyme expression, leading the authors to hypothesize a 
compensatory mechanism to overcome HIV/ARV-associated mitochondrial toxicity [50]. However, 
most of the studies reported different degrees of evidence of increased mitochondrial toxicity and,  
in some cases, the development of apoptosis in maternal, fetal or even placental tissue [45–49].  
The small sample size of these studies makes it difficult to link mitochondrial toxicity or the development 
of apoptosis with adverse pregnancy outcomes because of the reduced statistical power when  
classifying the HIV-cohort according to successful pregnancy results. Further studies with larger sample 
sizes are required. 
3.2.2. Antipsychotics, Antibiotics, Hypolipemia Drugs and Antidiabetics, Non-Steroidal  
Anti-inflammatory Drugs (NSAIDs), Anesthetics, Chemotherapy Drugs, Antiarrhythmics, 
Antimalarials and Fungicides 
Similarly, many other drugs currently used in clinical practice as acute treatments in non-pregnant 
subjects have been described to cause mitochondrial toxicity by impairing different pathways of 
mitochondrial function. Mitochondrial respiratory chain function has been reported to be blocked by 
some antibiotics (including piericidin A or antimycin A) [51], certain anaesthetic drugs [52] or some 
barbiturates [53], antineoplastic treatments (including flutamide, tamoxifen and doxorubicin) [54,55] 
and fungicidal agents (such as myxothiazole, sodium azide or rutamycin) [56]. Some of these agents 
may lead to the impairment of cell respiration (fibrates) [57]. Other drugs can act as uncouplers of the 
oxidative phosphorylation system (antibiotics such as valinomycin and gramicidin, local anaesthetics 
and antineoplastics including flutamide, tamoxifen and doxorubicin) [55]. Likewise, other drugs may 
prevent ATP production (antibiotics such as oligomycin or local anaesthetic drugs), inhibit protein 
synthesis (antibiotics including chloramphenicol, tetracycline, erythromycin, eperezolid, linezolid and 
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aminoglycosides) [19,58], decrease electron transfer (anticholesterolemics) or membrane potential, 
impair mitochondrial lipid metabolic pathways (barbiturates) or increase apoptosis (including 
benzodiazepines) [59]. Such mitochondrial disturbances have been reported to cause adverse effects 
including deafness [60], peripheral neuropathy [61], hyperlacatemia, lactic acidosis [62] and 
gastrointestinal, dermatological or hematological alterations, myopathic syndrome or gastrointestinal 
disturbances, among others [63]. Specific safety and mitochondrial toxic studies in human pregnancies 
are lacking for most of these drugs. Indeed, most of these treatments are contraindicated in pregnancy 
(for instance, chloramphenicol, tetracyclines, linezolid, most aminoglycosides, oral hypolipemiadrugs 
or fungicides). However, during pregnancy, women could be exposed to these substances in some 
exceptional cases: when they are not aware of their pregnancy status, as punctual and short interventions 
in case of emergency (for instance erythromycin) or as mandatory treatments for chronic diseases, 
among others. 
This is the case of drugs used for mental health disorders such as schizophrenia, bipolar disorder, and 
psychotic depression, which are not rare in women of childbearing age. Similar to ARV, antipsychotic 
drugs in the management of antenatal psychiatric disorders are not of choice but are strongly 
recommended or even mandatory in psychiatric patients during pregnancy. Antipsychotics are 
associated with increased gestational weight and diabetes and increased risk of preterm birth. The effects 
of antipsychotics on low birth weight or malformations are inconclusive. From a mitochondrial point of 
view, antipsychotics have been described to inhibit MRC complex I function, causing an increase in the 
levels of oxidative stress in non-pregnant adults [64]. However, no study was found regarding the 
analysis of mitochondrial toxicity of neuroleptic drugs in human pregnancies.  
On the other hand, although the hypoglycemiant drugs are not administered during gestation, insulin 
is allowed. Gestational diabetes is a condition characterized by high blood sugar (glucose) levels that is 
first recognized during pregnancy. The condition occurs in approximately 4% of all pregnancies and is 
associated with fetal macrosomia. In addition, hypertension and preeclampsia occur more commonly in 
women with gestational diabetes. Mitochondrial dysfunction has been reported during human pregnancy 
with gestational diabetes mellitus [65]. In general, some antidiabetic drugs have been related to 
mitochondrial damage through specific MRC impairment. For example, metformin specifically inhibits 
MRC complex I activity [66]. However, information regarding the consequences of insulin 
administration during human pregnancy and the potential mitochondrial toxicity derived from in utero 
exposure is scarce. Few works on this topic have been performed in animal models and report null effects 
(at least obvious) on progeny at delivery. On the contrary, indirect metabolic and mitochondrial toxicity 
has been reported with the development of diabetes during pregnancy due to high glucose levels that 
reduce fatty acid oxidation and increase triglyceride accumulation in human placenta [67], thereby 
causing a metabolic and energetic imbalance that may endanger embrionary development.  
Nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin or ibuprofen, are among the drugs 
most commonly prescribed worldwide to reduce inflammation and pain through cycloxygenase 
inhibition and a consequent decrease in prostaglandin production. Nonsteroidal anti-inflammatory drugs 
have been reported to cause an uncoupling of the oxidative phosphorylation pathway, an increase in 
resting state respiration, a decrease in ATP synthesis and mitochondrial membrane potential, inhibition 
of adenine nucleotide translocase and an alteration in mitochondrial lipid metabolic pathways with 
potential implications by way of the gastrointestinal damage associated with NSAID administration in 
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non-pregnant adults [59]. However, scarce data are available on the potential effects in human 
pregnancies. Ibuprofen is not prescribed during pregnancy due to adverse effects on fetal circulation, 
but aspirin is recommended in pregnancies complicated by preeclampsia, repetitive miscarriages or 
previous fetal death. 
Antiarrhythmic and antimalarial drugs such as quinidine have also been described to be mitotoxic 
agents, with quinidine being particularly associated with ATP-synthase inhibition [68]. The potential 
induction of oxidative stress has been associated with some antimalarial drugs [69], but little is known 
about their mechanisms of toxicity or adverse outcomes in pregnancy. There are few studies on the 
pharmacokinetics, safety and efficacy of antimalarials in human pregnancies. Several decades ago [70] 
one study assessed the effect of the antimalaria drug pyrimethamine in pregnancy [70,71], reporting 
altered embryonal hepatocytes with destructive changes in mitochondria. 
In summary, although potential exposures with mitotoxic drugs during fertilization or pregnancy may 
be considered harmful, few studies (if any) have evaluated the clinical consequences of the use of such 
products in pregnant women and their potentially derived mitochondrial toxicities. Consequently, drug 
exposure should be minimized or avoided during pregnancy, especially when considering the above 
mentioned medications, except under explicit medical prescription and clinical supervision. 
3.3. Abuse Drugs, such as Tobacco or Alcohol 
It is widely known that tobacco causes serious adverse alterations in the organism. Regarding fertility, 
it has been described that the exposure to cigarette smoke causes antral follicle destruction and oocyte 
dysfunction through oxidative stress [72]. Despite a reduction in tobacco consumption during pregnancy, it 
is estimated that about 20–50% of pregnant women smoke during pregnancy in developed countries [18].  
From a mitochondrial point of view, the carbon monoxide (CO) present in tobacco smoke binds to 
the heme group of the MRC complex IV, the enzyme responsible for the reduction of oxygen  
molecules into water, triggering a decrease in cell respiration and a consequent increase of ROS 
production and oxidative stress damage [73–76]. Tobacco consumption in human pregnancies has been 
associated with a wide range of adverse obstetric outcomes (preterm delivery, stillbirths, sudden infant 
death and respiratory problems during childhood), being IUGR the most frequent of these toxic 
manifestations [77,78]. Studies in human pregnancies have associated maternal smoking with mtDNA 
depletion and respiratory chain complex III deficiency in placenta [18]. In our experience [79], typical 
mitochondrial toxic hallmarks of smoking in pregnant women are also present in both placenta and cord 
blood cells of the newborn, suggesting that mitochondrial disturbances may be involved in IUGR. Such 
mitochondrial abnormalities due to in utero exposure to tobacco smoke include MRC IV inhibition, 
increased oxidative stress, decreased mtDNA content and raised apopototic levels which are responsible 
for potential adverse obstetric outcome. Placental apoptosis has been previously associated with a higher 
incidence of adverse obstetric outcomes, especially preeclampsia [80,81], in non-smoking women. 
Interestingly, IUGR may also be associated with apoptosis in smoking pregnant woman, suggesting that 
it may be the basis of both phenomena, regardless of the idiopathic or toxic origin.  
Alcohol abuse has been widely associated with several medical and social problems and its use has 
been related to the intoxication of the central nervous system, impaired brain activity, poor motor 
coordination, and behavioral changes. Acute alcohol consumption affects carbohydrate, fat and protein 
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metabolism. Mitochondria are essential for the conversion of acetaldehyde into acetate and the 
generation of increased amounts of NADH, as reviewed [82]. Therefore, during ethanol oxidation, there 
is an increase in the NADH/NAD+ ratio followed by alterations of the cellular redox state and triggering 
of a number of adverse effects, associated with alcohol consumption [83]. 
Alcohol does not bind to any tissue or plasma proteins because of its soluble nature, however, it can 
cross the blood brain barrier and placenta [84]. Alcohol dependence during pregnancy has been 
associated with a multitude of adverse obstetric outcomes and adverse effects in offspring (being the 
fetal alcohol syndrome the most extreme) including pre- and post-natal growth retardation, newborn 
microcephalia, neurologic abnormalities and intellectual disability [85]. Even moderate alcohol 
consumption during pregnancy carries a risk of alterations in neurodevelopment, as well as malformations 
and physical impairments. Early identification of chronic alcohol intake is essential for the establishment 
of preventive measures to diminish adverse effects among newborns [86].  
Many relatively recent studies in animal models, such as rats, mice and guinea pigs [87] have been 
performed to determine the consequences of chronic prenatal exposure to ethanol. In these experimental 
studies, alcohol-induced oxidative stress and mitochondrial dysfunction has been described in placental 
tissue [88]. The increase in trophoblast apoptosis (associated with increased expression of pro-apoptotic 
proteins and decreased antiapoptotic proteins) and the increase of oxidative stress and lipid peroxidation 
related to gestational exposure to ethanol [88] indicate that mitochondria are the main organelle involved 
in all these processes. It has been reported that neuronal abnormalities found in the fetal alcohol 
syndrome could be due to initial damage during astrocyte development, and this syndrome has been 
associated with a lower number of mitochondria and presenting altered morphology [89]. Despite all 
these results from animal models, significant data on mitochondrial toxicity derived from in utero fetal 
exposure in human pregnancies are remarkably lacking. 
3.4. Mitochondrial Toxicity of Poisonous Gases 
There are many asphyxiating and potentially lethal gases that produce molecular damage due to its 
condition of mitochondrial hazards. Some of these toxic gas agents include nitric oxide (NO), cyanide 
(CN), hydrogen sulphide (H2S) or carbon monoxide (CO), some of which are responsible for severe 
intoxications which may induce rapid death. The severity of the symptoms and the appearance of late 
sequelae depend on the intensity and duration of the exposure. Interestingly, all these toxic gases present 
the same mitotoxic pathophysiologic mechanism of damage through the inhibition of MRC complex IV, 
which is ultimately responsible for oxygen consumption and cell respiration [26,90–92]. A consequent 
increase in oxidative stress steady state levels has also been described [93]. Among these gases, the most 
frequent intoxication is produced by CO, triggered by abnormal combustion of complex organic 
compounds occurring in an atmosphere lacking oxygen. This exposure can be acute (punctual) or chronic 
(additive). Indeed, a special case of CO intoxication is that which is characteristic of smokers because 
CO is one of the thousands of toxic compounds present in tobacco smoke [94]. The association of 
obstetric problems with mitochondrial toxicity derived from tobacco consumption during pregnancy has 
been previously described in the section on “Abuse drugs”.  
No studies were found on mitochondrial toxicity derived from exogenous NO, CN, H2S or CO toxic 
gas exposure during pregnancy. However, a few studies did report the effects of NO and CO as 
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endogenous physiologic factors synthesized during pregnancy. Some experimental evidence support an 
association of the increase of these chemical substances with the enhanced oxidative stress that takes 
place during pregnancy arising from increased placental mitochondrial activity and production of ROS. 
Myatt et al. reported that these ROS (NO, CO and peroxynitrite) have pronounced effects on placental 
function promoting vascular reactivity and trophoblast proliferation and differentiation. The description 
of an improved oxidative metabolism, increased endothelial NO synthase expression and NO production 
in human placenta after combined aerobic and resistance exercise training during the second half of 
pregnancy is also remarkable [95]. However, all these effects are produced by endogenous NO and CO 
synthesized by placenta, rather than by the exogenous gases responsible for toxic insults.  
The production of ROS is part of the physiologic responses necessary at certain windows in placental 
development. However, excessive ROS production may occur in pathologic pregnancies, such as those 
complicated by preeclampsia and/or IUGR, overpowering antioxidant defenses and promoting 
deleterious outcomes [96]. We found no reports describing the molecular or clinical consequences of 
external NO or CO poisoning during pregnancy, but a potential increase in ROS generation and adverse 
obstetric outcome is plausible. 
3.5. Chemical Substances such as Pesticides 
Some pesticides (herbicides, insecticides or acaricides) can seriously damage the mitochondria.  
These compounds may induce clinical symptoms of acute intoxication but usually produce clinical 
manifestations after prolonged low-dose chronic exposure such as that produced by occupational 
contact. At present, many neurodegenerative disorders, especially Parkinson’s disease, have been 
associated with the toxic effect of certain chemical agents on neurons due to potential toxicant activity. 
Different mechanisms causing damage to the mitochondria have been described in pesticides, but the 
inhibition of MRC complex I enzymatic activity is one of the most common mitochondrial toxic 
capacities described among the most frequently used compounds (rotenone, pyridaben, fenazaquin and 
fenpyroximate), some of which increase ROS production (rotenone, pyridaben, paraquat) accompanied, 
in some cases, by the consequent development of apoptosis (paraquat and glyophosphate) [97].  
For instance, blood cholinesterases and tissue carboxylesterases (CE) are sensitive indicators of 
exposure to environmental organophosphate pesticides (OP). In a study including healthy women living 
on agricultural farms, the authors studied the impact of OP exposure on placental CE activity and lipid 
composition during the pulverization and recess periods. Plasma and placental CE activity decreased in 
the pulverization period, suggesting that these pesticides reached the placenta. The cardiolipin content 
increased and the phosphatidylethanolamine content decreased in the light mitochondrial fraction [98], 
suggesting that potential detrimental toxicity may affect fetal development. 
Nonetheless, further studies are needed to assess the impact of pesticides on human pregnancies due 
to frequent or even chronic exposure to these everyday compounds and the little information available 
reporting potential adverse effects on fertility or pregnancy outcomes. 
4. Discussion 
Several studies have suggested that the mitochondria are critical for successful fertilization and fetal 
development [14]. For instance, mitochondrial dysfunction has been associated with reproductive 
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outcome since their function influences the viability of both sperm and oocytes. Accordingly, a low 
mtDNA content in both males [99,100] and females [4,44] has been related to infertility. In addition, 
mutations in the mtDNA genome have also been described in spermatozoa with declined motility and 
fertility [101]. 
In general, disorders of mitochondrial function in oocytes may cause reproductive failure. 
Mitochondrial defects in oocytes can eventually lead to cell dysfunction and infertility and mitochondrial 
content has been demonstrated to reflect oocyte viability and fertilization outcome [4]. Both Reynier 
[100] and Santos [4] established an association between the mtDNA content and fertilization. The latter 
study suggested that mtDNA content could be a marker of oocyte quality and fertility. Other studies 
have suggested that a low mtDNA content is associated with the impaired oocyte quality observed in 
ovarian insufficiency [102]. 
Accordingly, adequate mitochondrial and mtDNA content in both male and female gametes is 
intrinsic for successful fertility. Nonetheless, once fertilization is achieved, mitochondrial function is 
still essential for fetal development and a favorable obstetric outcome. Some studies have analyzed the 
implication of mtDNA levels in fetal growth. Gemma et al. reported that newborns with abnormally low 
and high birth weight present less mtDNA content in the umbilical cord [79,103]. More recently,  
other authors corroborated these results in cord blood leucocytes of neonates with reduced body  
mass [103,104], suggesting that appropriate mtDNA levels are essential for appropriate birth weight 
development. Intrauterine growth restriction and pregnancy hypertensive disorders such as preeclampsia 
associated with IUGR share a common placental phenotype called “placental insufficiency”, originating 
early in pregnancy when the availability of high energy output is required. This period is characterized 
by decidual trophoblast invasion and intense cellular growth, replication and differentiation. Since a 
huge energetic production is required during gestation, the mitochondria may play a crucial role in this 
process, being the main energetic producer in the cell. 
Mitochondrial disturbances can arise from both inherited diseases and exposure to toxic substances. 
Genetically inherited diseases can be suspected and avoided through preconceptional genetic counseling. 
However, mitochondrial toxicities can be acquired by healthy pregnant women exposed to mitochondrial 
toxic compounds during gestation, with consequences for affected newborns similar to those of 
mitochondriopathies of genetic origin. Dozens of compounds in our everyday life are toxic for 
mitochondria, including some found in daily clinical practice. A large number of studies have reported 
the toxic adverse effects of these mitochondrial poisons in non-pregnant subjects. However, only a few 
studies have analyzed the effects derived from in utero exposure. Indeed, there are very scarce data 
regarding the use of antipsychotics, antibiotics, antidiabetics, anaesthetics, antimalarials or fungicides, 
among others, during gestation.  
It is unclear whether the lack of information related to these factors is related to the inability to undertake 
designated studies (exclusively observational or case-reports are available) or if the mitochondrial toxicity 
in pregnant women has minimal consequences on obstetric outcomes. On the contrary, the number of 
studies reporting information about HIV, ARV and tobacco exposure during gestation was higher, 
probably due to a larger number of pregnancies affected by such exposures. 
The negative mitochondrial and clinical effects of ARV have been focused on HIV-human 
pregnancies with some controversial results [45,50]. However, most studies associated ARV-derived 
mitochondrial toxicity with significant mtDNA depletion and mitochondrial dysfunction in maternal, 
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fetal and/or placental tissues, usually demonstrating a strong, significant and positive correlation in 
materno-fetal mitochondrial lesion. Antiretroviral drugs are able to cross the placental barrier. Our group 
reached similar conclusions regarding the mitochondrial toxicity observed in smoking pregnant women: 
newborns exposed to tobacco in utero showed a similar mitochondrial toxicity to that of their smoking 
mothers [79]. Again, substances derived from tobacco which are toxic to the mitochondria (such as CO) 
present transplacental activity and may reach the fetus in this crucial stage of development. 
Transplacental mitochondrial toxicities have also been demonstrated in pesticide exposure [98], once 
again demonstrating the strong relationship of materno-fetal toxicities.  
The adverse clinical effects of these mitochondrial toxicities have been reported both in exposed 
mothers and fetuses along gestation. Increased adverse obstetric outcomes are frequent in these 
pregnancies. Maternal clinical and mitochondrial recovery is feasible once the toxic exposure is 
discontinued (whenever possible). However, during fetal development a multitude of physiologic 
responses take place in mitochondrially endangered fetuses to overcome the energetic imbalance and/or 
oxidative and apoptotic insult. The homeostatic mechanisms responsible for fetal remodeling of the 
adaptative response cannot be reversed once the fetuses are born and the toxic exposure is disrupted  
(if possible). All this molecular and cell fetal remodeling derived from exposure to mitochondrial toxic 
compounds in utero may have long term consequences of unknown severity.  
There is currently no therapeutic option available for mitochondrial pathologies or for their potential 
transmission. Selenium supplementation has been proposed as a protector mechanism of trophoblast 
cells from oxidative stress [105]. However, to date, genetic counseling and preimplantacional diagnosis 
are the best therapeutic options to avoid the transmission of mitochondrial diseases. Future IVF strategies 
including the use of restriction enzymes to decrease the number of mutated mtDNA molecules in the 
maternal oocyte or mitochondrial replacement techniques (through Spindel and Pronuclear Transfer) 
may prevent the transmission of mitochondrial disease (in the former by using three reproductive cells; 
the extra oocyte is necessary to provide healthy mitochondria) [106]. However, when these therapeutic 
options become available they will probably be devoted to avoiding transmission of inherited 
mitochondrial diseases. Nonetheless, despite having similar molecular and clinical consequences, 
mitochondrial diseases acquired by toxic exposure to any mitochondrial poison, cannot, at present, be 
treated or prevented. 
Consequently, further studies are needed to determine the fetal and future neonatal consequences of 
exposure to mitochondrial toxic agents in utero which are frequently present in our everyday life. 
Currently, it is best to avoid exposure to all the above mentioned toxic mitochondrial hazards. 
Nevertheless, to prevent damage, in case of therapeutic or accidental exposure, further research is 
required to find compounds which are less harmful to the mitochondria and to establish or translate 
biomarkers into clinical practice to follow mitochondrial lesions in pregnant women. 
5. Conclusions 
Mitochondrial toxicity derived from exposure to toxic agents can potentially involve much more 
severe consequences in the context of pregnancy than in adulthood as they may condition fetal 
remodeling, physiologic alterations and irreversible changes in the life of the developing individual.  
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Further studies are needed to elucidate the impact of mitochondrial toxic substances during the fertile 
stage and especially during pregnancy in humans in order to understand the precise molecular 
mechanisms leading to adverse clinical events. 
As the current treatments are symptomatic and supportive rather than therapeutic, the prevention of 
acquired mitochondrial diseases and exposure to mitochondrial toxicity is, to date, the best prophylactic 
therapeutic option of choice. 
Since prevention is not always possible in therapeutic or accidental exposures, there is the crucial 
need to find substances which are less toxic to the mitochondria, to search for biomarkers which facilitate 
monitoring during pregnancy and to assess the risk-benefit imbalance in cases of treatment prescription. 
Indeed, some biomarkers have already been developed and should be applied to the clinical field. 
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